Goldman Sachs
KURA icon

Goldman Sachs’s Kura Oncology KURA Stock Holding History

Goldman Sachs’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Buy
2,265,171
+831,700
+58% +$7.85M ﹤0.01% 2426
2026
Q1 		$11.7M Sell
1,433,471
-403,793
-22% -$3.47M ﹤0.01% 2937
2025
Q4 		$19.1M Sell
1,837,264
-777,462
-30% -$8.16M ﹤0.01% 2428
2025
Q3 		$23.1M Buy
2,614,726
+1,681,056
+180% +$12M ﹤0.01% 2118
2025
Q2 		$5.39M Buy
933,670
+104,889
+13% +$643K ﹤0.01% 3338
2025
Q1 		$5.47M Sell
828,781
-34,304
-4% -$267K ﹤0.01% 3264
2024
Q4 		$7.52M Buy
863,085
+153,601
+22% +$2.21M ﹤0.01% 3057
2024
Q3 		$13.9M Sell
709,484
-122,401
-15% -$2.48M ﹤0.01% 2395
2024
Q2 		$17.1M Buy
831,885
+46,009
+6% +$946K ﹤0.01% 2008
2024
Q1 		$16.8M Buy
785,876
+254,314
+48% +$4.94M ﹤0.01% 1995
2023
Q4 		$7.64M Buy
531,562
+70,765
+15% +$696K ﹤0.01% 2764
2023
Q3 		$4.2M Sell
460,797
-469,561
-50% -$4.77M ﹤0.01% 3141
2023
Q2 		$9.84M Sell
930,358
-156,442
-14% -$1.85M ﹤0.01% 2467
2023
Q1 		$13.3M Sell
1,086,800
-60,691
-5% -$757K ﹤0.01% 2163
2022
Q4 		$14.2M Sell
1,147,491
-288,301
-20% -$4.19M ﹤0.01% 2254
2022
Q3 		$19.6M Buy
1,435,792
+470,766
+49% +$7.26M 0.01% 1883
2022
Q2 		$17.7M Buy
965,026
+483,836
+101% +$6.96M ﹤0.01% 2003
2022
Q1 		$7.74M Buy
481,190
+174,913
+57% +$2.53M ﹤0.01% 2949
2021
Q4 		$4.29M Buy
306,277
+24,560
+9% +$398K ﹤0.01% 3561
2021
Q3 		$5.28M Buy
281,717
+111,374
+65% +$2.1M ﹤0.01% 3318
2021
Q2 		$3.55M Sell
170,343
-873,665
-84% -$21.7M ﹤0.01% 3664
2021
Q1 		$29.5M Sell
1,044,008
-211,289
-17% -$6.69M 0.01% 1601
2020
Q4 		$41M Buy
1,255,297
+651,001
+108% +$22.9M 0.01% 1277
2020
Q3 		$18.5M Sell
604,296
-27,416
-4% -$605K 0.01% 1794
2020
Q2 		$10.3M Buy
631,712
+535,271
+555% +$7.72M ﹤0.01% 2247
2020
Q1 		$960K Sell
96,441
-557,411
-85% -$6.38M ﹤0.01% 3792
2019
Q4 		$8.99M Buy
653,852
+437,182
+202% +$6.48M ﹤0.01% 2514
2019
Q3 		$3.29M Sell
216,670
-1,077
-0.5% -$19.2K ﹤0.01% 3172
2019
Q2 		$4.29M Sell
217,747
-423,484
-66% -$7.03M ﹤0.01% 2951
2019
Q1 		$10.6M Buy
641,231
+621,082
+3,082% +$9.57M ﹤0.01% 2356
2018
Q4 		$283K Sell
20,149
-16,277
-45% -$216K ﹤0.01% 4666
2018
Q3 		$637K Sell
36,426
-577
-2% -$11.1K ﹤0.01% 4292
2018
Q2 		$673K Buy
37,003
+8,900
+32% +$151K ﹤0.01% 4330
2018
Q1 		$527K Sell
28,103
-1,119
-4% -$21.8K ﹤0.01% 4461
2017
Q4 		$447K Buy
29,222
+9,590
+49% +$141K ﹤0.01% 4910
2017
Q3 		$293K Buy
+19,632
New +$184K ﹤0.01% 5487
2017
Q2 		– Sell
-60,530
Closed -$533K – 6867
2017
Q1 		$533K Buy
+60,530
New +$444K ﹤0.01% 4967
2016
Q3 		– Sell
-23,800
Closed -$64K – 7102
2016
Q2 		$64K Buy
23,800
+11,019
+86% +$34.3K ﹤0.01% 6324
2016
Q1 		$52K Buy
+12,781
New +$60.6K ﹤0.01% 6411

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Goldman Sachs's KURA Position: Q2 2026 in Review

Goldman Sachs increased its Kura Oncology (KURA) stake by 58% in Q2 2026, buying an estimated $7.85M and bringing the position to 2,265,171 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2426.

Goldman Sachs first reported a position in KURA in Q1 2016 and has held it in 39 quarters since. The position peaked at $41M in Q4 2020. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Goldman Sachs held 2,265,171 shares of Kura Oncology worth $24.8M as of Q2 2026.
  • Goldman Sachs bought 831,700 Kura Oncology shares in Q2 2026, an estimated $7.85M.
  • Kura Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2426 holding.
  • Goldman Sachs first reported a position in Kura Oncology in Q1 2016 and has held it in 39 quarters since.
  • Goldman Sachs's Kura Oncology position peaked at $41M in Q4 2020.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.